Concomitant interleukin-2-doxorubicin (ADR) schedule in patients (PTS) with advanced soft tissue sarcomas (ASTS): A pharmacokinetic study

被引：0
|
作者：
LeCesne, A [1 ]
Vassal, G [1 ]
Farace, F [1 ]
Spielmann, M [1 ]
LeChevalier, T [1 ]
Tursz, T [1 ]
Escudier, B [1 ]
机构：
[1] INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE
来源：
EUROPEAN JOURNAL OF CANCER | 1995年 / 31A卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：586 / 586
页数：1
相关论文
共 50 条
  • [41] INTERLEUKIN-2 PRODUCTION BY PERIPHERAL-BLOOD LYMPHOCYTES FROM PATIENTS WITH SOFT-TISSUE SARCOMAS
    BEREZHNAYA, NM
    GORETZKY, BA
    CONOVALENKO, VF
    PALIVETZ, AY
    TOLSTOPYATOV, BA
    EKSPERIMENTALNAYA ONKOLOGIYA, 1987, 9 (04): : 60 - 62
  • [42] MODIFYING EFFECT OF SERUM IN PATIENTS WITH SOFT-TISSUE SARCOMAS ON INTERLEUKIN-2 PRODUCTION AND ITS ACTIVITY
    GORETSKY, BA
    BEREZHNAYA, NM
    PALYVETS, AY
    KONOVALENKO, VF
    EKSPERIMENTALNAYA ONKOLOGIYA, 1989, 11 (01): : 59 - 61
  • [43] Results of a 2-arm phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas
    Patel, SR
    Beach, J
    Papadopoulos, N
    Burgess, MA
    Trent, J
    Jenkins, J
    Benjamin, RS
    CANCER, 2003, 97 (11) : 2848 - 2852
  • [44] Phase II Trial of Topotecan by Continuous Infusion in Patients with Advanced Soft Tissue Sarcomas, a SWOG Study
    G. Thomas Budd
    Cathryn Rankin
    Laura F. Hutchins
    Lucas Wong
    Paul J. Petruska
    Karen Antman
    Investigational New Drugs, 2002, 20 : 129 - 132
  • [45] Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study
    A López-Pousa
    R Losa
    J Martín
    J Maurel
    J Fra
    M Sierra
    A Casado
    J García del Muro
    A Poveda
    C Balañá
    J Martínez-Trufero
    E Esteban
    J M Buesa
    British Journal of Cancer, 2006, 94 : 1797 - 1802
  • [46] AN INTERGROUP PHASE-III RANDOMIZED STUDY OF DOXORUBICIN AND DACARBAZINE WITH OR WITHOUT IFOSFAMIDE AND MESNA IN ADVANCED SOFT-TISSUE AND BONE SARCOMAS
    ANTMAN, K
    CROWLEY, J
    BALCERZAK, SP
    RIVKIN, SE
    WEISS, GR
    ELIAS, A
    NATALE, RB
    COOPER, RM
    BARLOGIE, B
    TRUMP, DL
    DOROSHOW, JH
    AISNER, J
    PUGH, RP
    WEISS, RB
    COOPER, BA
    CLAMOND, GH
    BAKER, LH
    JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) : 1276 - 1285
  • [47] Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas:: a GEIS study
    Lopez-Pousa, A.
    Losa, R.
    Martin, J.
    Maurel, J.
    Fra, J.
    Sierra, M.
    Casado, A.
    Garcia del Muro, J.
    Poveda, A.
    Balana, C.
    Martinez-Trufero, J.
    Esteban, E.
    Buesa, J. M.
    BRITISH JOURNAL OF CANCER, 2006, 94 (12) : 1797 - 1802
  • [48] Randomized phase 2b trial comparing first-line treatment with aldoxorubicin versus doxorubicin in patients with advanced soft tissue sarcomas.
    Chawla, Sant P.
    Papal, Zsuzsanna
    Sankhala, Kamalesh
    Vasylyev, Leonid
    Mukhametsina, Guzel
    Aliev, Mamed
    Khamly, Kenneth
    Wieland, Scott
    Levitt, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] Assessment of cardiotoxicity (CT) associated with doxorubicin (dox) in patients (pts) with advanced soft tissue sarcoma (STS) in a phase III randomized trial
    Jones, R. L.
    Wagner, A.
    Kawai, A.
    Shahir, A.
    Soldatenkova, V.
    Wright, J.
    Tap, W. D.
    ANNALS OF ONCOLOGY, 2019, 30 : 685 - +
  • [50] A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule
    L. Serrone
    M. Zeuli
    T. Gamucci
    M. Nardi
    F. Cognetti
    Cancer Chemotherapy and Pharmacology, 2001, 47 : 206 - 210
12345